Published in Patient Care Law Weekly, March 21st, 2010
"Appropriate use of ESAs [which stimulate red blood cell production] and intravenous iron can effectively manage the anemia of chronic kidney disease and end-stage renal disease (ESRD), but several randomized trials have reported an increased risk of mortality and cardiovascular events in patients treated to achieve higher hematocrit levels. The earlier of these reports...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.